5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
SELL | SELL | SELL | SELL | SELL |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 2.09▼ | 2.09▼ | 2.09▼ | 2.10▼ | 2.11▼ |
MA10 | 2.10▼ | 2.10▼ | 2.11▼ | 2.09▼ | 2.13▼ |
MA20 | 2.11▼ | 2.11▼ | 2.10▼ | 2.13▼ | 2.17▼ |
MA50 | 2.09▼ | 2.10▼ | 2.11▼ | 2.15▼ | 2.27▼ |
MA100 | 2.12▼ | 2.15▼ | 2.14▼ | 2.18▼ | 2.36▼ |
MA200 | 2.14▼ | 2.14▼ | 2.17▼ | 2.26▼ | 4.92▼ |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | -0.003▼ | -0.002▼ | -0.001▼ | -0.002▼ | -0.005▼ |
RSI | 46.121▼ | 45.956▼ | 46.007▼ | 43.381▼ | 43.388▼ |
STOCH | 26.250 | 26.250 | 33.615 | 41.891 | 27.785 |
WILL %R | -72.727 | -72.727 | -72.727 | -61.818 | -77.419▼ |
CCI | -70.470 | -70.470 | -93.909 | -130.337▼ | -161.232▼ |
Monday, July 28, 2025 02:24 PM
By M. Marin NASDAQ:ORMP READ THE FULL ORMP RESEARCH REPORT Company maintains substantial liquidity Oramed Pharmaceuticals (NASDAQ:ORMP) had cash of $74.5 million at the end of March 2025, up from ...
|
Monday, December 02, 2024 12:11 PM
ORMP intends to launch a Phase 3 oral insulin trial in the U.S. under a differentiated protocol that is aligned with the positive subpopulation data and informed by feedback from discussions with ...
|
Monday, May 15, 2023 02:05 AM
NEW YORK, May 15, 2023 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com) announced today that Hefei Tianhui Biotechnology Co. Ltd. (HTIT), a strategic ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
15/08/25 | 2.00 | 2.1242 | 1.975 | 2.08 | 132,590 |
14/08/25 | 2.10 | 2.14 | 2.0882 | 2.12 | 75,112 |
13/08/25 | 2.10 | 2.143 | 2.0901 | 2.12 | 59,097 |
12/08/25 | 2.09 | 2.1097 | 2.065 | 2.10 | 46,127 |
11/08/25 | 2.10 | 2.1036 | 2.06 | 2.09 | 45,663 |
08/08/25 | 2.11 | 2.12 | 2.09 | 2.09 | 36,466 |
07/08/25 | 2.09 | 2.13 | 2.06 | 2.08 | 99,883 |
06/08/25 | 2.08 | 2.12 | 2.075 | 2.085 | 36,669 |
05/08/25 | 2.10 | 2.1199 | 2.0702 | 2.08 | 32,632 |
04/08/25 | 2.14 | 2.14 | 2.08 | 2.09 | 75,410 |
|
|
||||
|
|
||||
|
|